AVLN (Avalyn Pharma) Interest Coverage: N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Avalyn Pharma's Operating Income for the six months ended in Dec. 2025 was $-91.29 Mil. Avalyn Pharma's Interest Expense for the six months ended in Dec. 2025 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Avalyn Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Avalyn Pharma's Interest Coverage or its related term are showing as below:


AVLN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avalyn Pharma  (NAS:AVLN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Avalyn Pharma Interest Coverage Related Terms

Avalyn Pharma Interest Coverage Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Avalyn Pharma Interest Coverage Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Interest Coverage
No Debt N/A

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
Interest Coverage No Debt N/A

AVLN vs TRAX, IMTX, ARDX: Interest Coverage Comparison

For the Biotechnology subindustry, Avalyn Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalyn Pharma Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's Interest Coverage falls into.


AVLN
11GF Score
Avalyn Pharma Inc AVLN
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avalyn Pharma's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Avalyn Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-91.29 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.23 Mil.

GuruFocus does not calculate Avalyn Pharma's interest coverage with the available data.

Avalyn Pharma's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Avalyn Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-91.29 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.23 Mil.

GuruFocus does not calculate Avalyn Pharma's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price